Terns Pharmaceuticals, Inc.
TERN
株式のランク
#3585
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the... Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
株価
$52.95
最終同期: 2026-05-15
時価総額
$4.77B
変化（1日）
0.00%
変化（1年）
529.61%
国
US
取引 Terns Pharmaceuticals, Inc. (TERN)
カテゴリー
Healthcare
Terns Pharmaceuticals, Inc.（TERN）の配当履歴
Terns Pharmaceuticals, Inc.（証券コード：TERN）は合計で0回の配当を行いました。
すべての配当の合計（株式分割調整済み）は：0.00
配当利回り（TTM）：0
すべての配当の合計（株式分割調整済み）は：0.00
配当利回り（TTM）：0
2026から2026までのTerns Pharmaceuticals, Inc.（TERN）の配当履歴
年間配当支払い
| 年 | 配当（株式分割調整済み） | 変化 |
|---|---|---|
| 提供された日付のデータは十分ではありません。 | ||
すべての配当支払いの一覧
| 年 | 配当 | 変化 |
|---|---|---|
| 提供された日付のデータは十分ではありません。 | ||
同業他社や競合企業の配当履歴
| 企業 | 配当支払い回数 | 国 |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 64.00% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
